Labiotech.eu

News and Trends 29 Jul 2022

Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatment

U.S. company Sarepta Therapeutics, Inc. said it intends to submit a Biologics License Application (BLA) seeking accelerated approval for SRP-9001 (delandistrogene moxeparvovec) to treat ambulant individuals with Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche. “We are delighted to confirm that based on the feedback we […]

July 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jul 2022

Biotech startup Novasenta raises $40M to advance novel cancer therapeutics

Novasenta Inc., a U.S. startup biotech company focused on the discovery and validation of novel targets to develop cancer therapies, has completed $40 million in Series A financing. The round was led by UPMC Enterprises. The funding will allow Novasenta to advance its pipeline of antibody-based therapeutics and expand its computational platforms for target discovery, […]

July 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jul 2022

Commercial personalized cancer cell profile developed in Taiwan

Patients with stage 2 solid tumors could benefit from the world’s first commercial personalized cancer cell profiling, developed in Taiwan. Taipei-based CancerFree Biotech Ltd has developed the technology that will help stage 2 patients and above by shortening the selection process. The technology will be showcasing at US Bio 2022. This is the world’s first […]

July 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jul 2022

Beyond Biotech podcast 7: World Hepatitis Day

This week’s podcast features three interviews related to hepatitis. Our guests are Ahmed Elsharkawy, consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham in the UK; Ziv Ben-Ari, director of the Liver Diseases Center at the Sheba Medical Center in Israel, and James McIlroy, chief executive officer at EnteroBiotix. World Hepatitis […]

July 29, 2022

News and Trends 28 Jul 2022

AGC Biologics announces gene therapy partnership with Altheia Science

A new development partnership between gene therapy company Altheia Sciences, which pioneers cell and gene treatments, and AGC Biologics, will look at strategies to treat autoimmune disease and cancer. Specifically, the partnership will help advance development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing. PD-L1 […]

July 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Jul 2022

Mission Bio launches new cancer assay

Life sciences company Mission Bio, Inc. has announced the availability of the industry’s first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells. Mission Bio said this heralds a new era for the understanding of disease progression. The single-cell multi-omics MRD (scMRD) assay for acute myeloid leukemia […]

July 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jul 2022

Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA

A drug to target a rare genetic form of a neurological disease that affects the nerve cells, leading to the loss of everyday functions, could be the first of its kind available if approved. The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Massachusetts-based Biogen Inc. for tofersen, an […]

July 28, 2022 - 4 minutesmins - By Liza Laws

News and Trends 28 Jul 2022

Step Pharma moves into oncology clinical trials

Step Pharma, which works on CTPS1 inhibition for the targeted treatment of cancer, has announced its lead asset STP938 has cleared both an Investigational New Drug (IND) application by the Food and Drug Administration (FDA), and a clinical trial application (CTA) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This means Step Pharma […]

July 28, 2022 - 3 minutesmins - By Jim Cornall

circulating tumor cells, cancer, clinical trials

News and Trends 28 Jul 2022

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […]

July 28, 2022 - 3 minutesmins - By Liza Laws

In Depth 28 Jul 2022

How can vaccines keep up with evolving Covid-19 variants?

Vaccines for COVID-19 have saved lives all over the world, but their protection is threatened by the rise of variants of concern. Companies are developing ways to combat the evolving virus, such as booster shots and universal coronavirus vaccines. During 2021, a plethora of COVID-19 vaccines was rolled out around the world. Since then, mass […]

July 28, 2022 - 7 minutesmins - By Jonathan Smith

Best in Biotech 28 Jul 2022

Five companies personalizing treatments with 3D printed drugs

There has been a noticeable shift in recent years towards the personalization of medicine, with the pharmaceutical industry showing interest in pills that are tailored to a patient’s needs. Here are five companies that are leveraging 3D printing to produce customizable drugs. Conventional drug production relies on large-scale batch manufacturing, which is very efficient at […]

July 28, 2022 - 5 minutesmins - By Omnia Ibrahim

News and Trends 28 Jul 2022

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

Sandoz, a global pharmaceutical company working in generic and biosimilar medicines, announced this week that the US Food and Drug Administration (FDA) has accepted its biologics application (BLA) for treatment for people with multiple sclerosis (MS). The application is for a biosimilar natalizumab developed by Polpharma Biologics and includes all indications covered by the reference […]

July 28, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatment

Biotech startup Novasenta raises $40M to advance novel cancer therapeutics

Commercial personalized cancer cell profile developed in Taiwan

Beyond Biotech podcast 7: World Hepatitis Day

AGC Biologics announces gene therapy partnership with Altheia Science

Mission Bio launches new cancer assay

Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA

Step Pharma moves into oncology clinical trials

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

How can vaccines keep up with evolving Covid-19 variants?

Five companies personalizing treatments with 3D printed drugs

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!